Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature.
about
Cost-effectiveness of caspofungin versus liposomal amphotericin B in the treatment of systemic fungal infections: a systematic review of economic analyses.Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions.Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients.Pharmacoeconomics of voriconazole.Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence.Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals.Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients.Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey.Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia.Use of antifungal agents in pediatric and adult high-risk areas.Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options.Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.Economic evaluation of micafungin vs. Liposomal Amphotericin B (LAmB) for the treatment of candidaemia and Invasive Candidiasis (IC)Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis
P2860
Q36056617-E33695A1-442F-460F-96F7-88EACBA39D3CQ36326220-D9568D77-D3F5-4071-B068-62DC966537BBQ36613885-52687AAA-4098-465A-9BF5-924BC96F34EDQ37702237-F7D9D9D3-767E-42B2-91D6-9C5FF2ECF95DQ37886974-F4A82EF2-5C60-4763-83A6-FF614D3C5660Q37999387-011187DA-1CE2-4EC7-B210-AF121D32AD58Q38097528-BD2EA9C1-683E-458B-9E44-0D2BE54BE30FQ38682970-FB494B8B-C663-49AE-A677-446CD8115A3FQ40317253-D874316E-DD2E-42E5-90B5-280966272FBDQ44506237-A80418F7-80C0-4E70-9C26-9F344550A1F1Q44612152-5445FEFD-4E8A-4FBD-87D9-0F3AAEFD06E6Q45861947-64A825E3-F75A-499B-9AF7-47F75361B9B6Q47399293-2167D34B-1E6B-42AE-A954-F78B05F276EEQ57746129-E57CF6A5-6E7C-417C-A992-4CF8AC379D88Q57746135-DC7E6C81-FFB6-447D-974C-E8B103A4E6C9
P2860
Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Economic evaluations of treatm ...... atic review of the literature.
@ast
Economic evaluations of treatm ...... atic review of the literature.
@en
type
label
Economic evaluations of treatm ...... atic review of the literature.
@ast
Economic evaluations of treatm ...... atic review of the literature.
@en
prefLabel
Economic evaluations of treatm ...... atic review of the literature.
@ast
Economic evaluations of treatm ...... atic review of the literature.
@en
P2093
P1433
P1476
Economic evaluations of treatm ...... atic review of the literature.
@en
P2093
Emma McKeen
Margaret Tabberer
Suzy Paisley
P304
P356
10.2165/00019053-200422070-00002
P50
P577
2004-01-01T00:00:00Z
P6179
1027074790